Compare Apartment Investment and Management Co (AIV) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs Incyte Corporation — how do they compare? Apartment Investment and Management Co trades at $2.84 (market cap $422.94M), while Incyte Corporation trades at $117.33 (market cap $23.10B). The key difference: Incyte Corporation is far larger — about 54.6× Apartment Investment and Management Co's market cap, and Incyte Corporation is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | INCY | |
|---|---|---|
Market Cap | $422.94M | $23.10B |
Sector | Real Estate | Health |
52-Week High | $8.76 | $118.05 |
52-Week Low | $2.87 | $67.38 |
Enterprise Value | $669.06M | $19.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
